Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 4/20 | 0.32 |
| ▸ | LMNA | P02545 | 4/20 | 0.32 |
| ▸ | MAT2A | P31153 | 1/20 | 0.31 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.31 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.31 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | FPR2 | P25090 | 1/20 | 0.31 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.31 |
| ▸ | ACKR3 | P25106 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22101877 | 0.90 | KDM4E (0.38) | KDM4EMEN1KMT2AMAPTALDH1A1 | |
| SCHEMBL22101360 | 0.89 | MAPT (0.35) | MAPTTP53LMNAMAT2ARXFP1 | |
| SCHEMBL22101503 | 0.88 | L3MBTL1 (0.36) | KDM4EL3MBTL1MAPTALDH1A1TSHR | |
| SCHEMBL22101445 | 0.87 | TSHR (0.39) | KDM4EMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL22101899 | 0.87 | MAPT (0.35) | KDM4EMEN1KMT2AL3MBTL1MAPT | |
| SCHEMBL22101383 | 0.85 | PIK3CB (0.30) | — | |
| SCHEMBL22101491 | 0.84 | ALDH1A1 (0.33) | KDM4EALDH1A1FPR2SCN9ACYP1A2 | |
| SCHEMBL22101410 | 0.83 | — | — | |
| SCHEMBL22101396 | 0.82 | — | — | |
| SCHEMBL22101465 | 0.82 | KDM4E (0.36) | KDM4EMAPTALDH1A1HSD17B10TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2023-02-02 | — | — | US | disclosed |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2022-05-17 | — | — | US | disclosed |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | CHIA TAI TIANQING PHARMACEUTICAL GROUP CO., LTD. (CN) | 2020-09-03 | — | — | US | disclosed |
| EP-3666772-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. (CN) | 2020-06-17 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230035184-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | KDM4E 2942/4885MEN1 1758/4885KMT2A 843/4885 |
| US-20200277290-A1 | DIARYLTHIOHYDANTOIN COMPOUND AS ANDROGEN RECEPTOR ANTAGONIST | AR, NR5A1, LHCGR | KDM4E 2942/4885MEN1 1758/4885KMT2A 843/4885 |
| US-11332465-B2 | Diarylthiohydantoin compound as androgen receptor antagonist | AR, NR5A1, LHCGR | KDM4E 2942/4885MEN1 1758/4885KMT2A 843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.